Nextcure Inc   (NXTC)
Other Ticker:  
Price: $1.4700 $-0.05 -3.289%
Day's High: $1.55 Week Perf: 0.68 %
Day's Low: $ 1.44 30 Day Perf: 25.64 %
Volume (M): 300 52 Wk High: $ 1.92
Volume (M$): $ 441 52 Wk Avg: $1.46
Open: $1.48 52 Wk Low: $0.98

 Market Capitalization (Millions $) 41
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 2

Nextcure Inc
NextCure Inc. is a biopharmaceutical company that focuses on developing immunomedicines for the treatment of cancer and other immune-related diseases. The company's approach involves understanding and targeting key immune cell populations to develop novel therapies. They aim to uncover new insights into the complex interactions between immune cells and cancer cells, with the ultimate goal of developing innovative treatments that can benefit patients. NextCure's research and development efforts involve the discovery and development of therapeutic antibodies and other immune modulators. Overall, NextCure Inc. is dedicated to advancing the field of immunotherapy and improving patient outcomes in the battle against cancer and immune-related disorders.

   Company Address: 9000 Virginia Manor Road Beltsville 20705 MD
   Company Phone Number: 399-4900   Stock Exchange / Ticker: NASDAQ NXTC
   NXTC is expected to report next financial results on March 01, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

Groundbreaking Study Reveals Anti-Siglec-15 Antibody Boosts Bone Strength Following Acute Spinal Cord Trauma

Published Thu, Dec 21 2023 12:05 PM UTC

In an exploratory endeavor embodied by a dedicated pursuit of transformative healthcare solutions, NextCure, Inc. has revealed a new therapeutic strategy that could redefine the approach for mitigating bone problems triggered by acute spinal cord injury. This landmark information has been published within an article titled Anti-Siglec-15 Antibody Prevents Marked Bone Loss af...

Clinical Study

NextCure's Immunomedicines: Revolutionizing Cancer Treatment through Immune System Mastery

Published Thu, Dec 14 2023 11:45 AM UTC

NextCure: A Promising Pipeline of Immunomedicines to Revolutionize Cancer Treatment
Beltsville, MD - NextCure, Inc. (Nasdaq: NXTC), a pioneering clinical-stage biopharmaceutical company focused on revolutionizing cancer treatment through the development of novel immunomedicines, recently announced significant updates regarding its clinical pipeline. The company, driven b...

Nextcure Inc

Nextcure Inc. Shatters Expectations with Extraordinary Third Quarter Performance, Leaving Competitors in Awe

In the ever-evolving stock market, it is crucial to keep an eye on both prominent and lesser-known companies. Nextcure Inc, a small corporation in the Major Pharmaceutical Preparations sector, recently reported its earning figures for the third quarter of 2023. Despite being overlooked by many investors, Nextcure Inc has displayed commendable efficiency by reducing its operating shortfall compared to the previous year. This article will explore the company's progress and shed light on its future prospects.
Improved Efficiency and Financial Results
Nextcure Inc successfully managed to decrease its operating shortfall by $3.621 million, reporting an operating shortfall of $-15.618 million for the third quarter of 2023. In comparison, during the same period in the previous year, the company had recorded a larger operating shortfall of $-19.239 million. This significant improvement suggests that Nextcure Inc has taken measures to streamline its operations, resulting in enhanced efficiency and cost management.

Nextcure Inc

Nextcure Inc Delivers Promising Q2 2023 Financial Results, Demonstrates Strong Market Performance Potential

Nextcure Inc: Bullish Outlook on Financial Results and Market Performance
In the ever-evolving world of the Major Pharmaceutical Preparations industry, smaller companies often look to the bellwether companies for guidance. Nextcure Inc, a promising player in this sector, recently announced its financial results for the second quarter of 2023, providing a glimpse into its potential for success. Despite reporting an operating loss of $-19.158 million, there are several indicators that point towards a bullish outlook for Nextcure Inc.
To put these financial results into perspective, let's compare them to the same period last year. In the second quarter of 2022, Nextcure Inc had reported an operating loss of $-18.128 million. However, in the second quarter of 2023, the company managed to decrease its losses even further to $-17.859 million. This positive surprise is a strong indication of the company's progress and potential for growth.

Nextcure Inc

Nextcure Inc's Operating Shortfall Shrinks to $-20.771 Million, Reflecting Recent Fiscal Period Progress

Nextcure Inc: A Biotech Company Making Strides in Cancer Research
Nextcure Inc, a biopharmaceutical company based in Beltsville, Maryland, is making significant strides in cancer research. The company's focus is on developing cancer treatments using its unique approach to genetic and immune system research. The company is known for its work on the development of immuno-oncology treatments, which use the body's immune system to fight against cancers.
The company uses its proprietary platform, Functional, Integrated Genomics, and Target Discovery Engine (FIGHT), which utilizes high-throughput technology to map the cancer tumor microenvironment and help identify potential targets for cancer treatments. This technology analyzes gene expression patterns and cellular networks at a high level of resolution, allowing for a better understanding of the biology of cancer.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com